GlassScriptPhysician profile
Allison Leeann Plaster
NPI 1700333770
$11,269.87
in general payments reported to CMS, 2019-2025
30 companies · $3,173 in 2025
The $3,173 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $834 · 2022: $1,498 · 2023: $2,494 · 2024: $3,271 · 2025: $3,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,838 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,838.18 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,593.90 | 2021-2025 | |
| Janssen Biotech, INC. | $1,618.01 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $1,492.78 | 2021-2025 | Enbrel, Krystexxa, Tavneos |
| Lilly USA, LLC | $1,030.16 | 2021-2025 | Taltz, Zepbound |
| Ucb, INC. | $917.59 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $806.23 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $334.78 | 2021-2025 | Orencia |
| Horizon Therapeutics Plc | $300.66 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $294.94 | 2022-2024 | Lupkynis |
| Sandoz INC. | $288.22 | 2023-2025 | Hyrimoz, Jubbonti |
| Astrazeneca Pharmaceuticals LP | $266.55 | 2021-2025 | Saphnelo, Flumist Quadrivalent |
| Pfizer INC. | $259.82 | 2021-2025 | |
| Radius Health, INC. | $179.11 | 2021-2025 | Tymlos |
| Fresenius Kabi USA, LLC | $169.58 | 2023-2025 | Idacio |
| Organon LLC | $151.56 | 2022-2025 | Renflexis, Hadlima, Nexplanon |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $109.13 | 2021-2022 | |
| Genentech USA, INC. | $66.19 | 2023-2024 | Actemra |
| Alexion Pharmaceuticals, INC. | $54.92 | 2022-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.20 | 2023-2024 | Ofev, Cyltezo |
| Ani Pharmaceuticals, INC. | $35.83 | 2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $34.24 | 2024 | Opsumit, Uptravi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.83 | 2021 | |
| Nestle Healthcare Nutrition INC. | $25.81 | 2021 | |
| Sobi, INC | $25.77 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $24.12 | 2023 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $23.77 | 2023 | |
| Genzyme Corporation | $22.39 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $21.18 | 2024 | Arcalyst |
| Csl Behring | $20.30 | 2021 | |
| Novo Nordisk INC | $15.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Plaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.